Back to TAKView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
5 competitors in Fabry Disease
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA8/3/2001
Replagal
Replagal is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of Fabry disease (?-galactosidase-A deficiency).
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medicationsPhase 3
Hypertension
IGSCPhase 3
Primary Immunodeficiency Disease
HYQVIAPhase 3
Primary Immunodeficiency Diseases (PID)
Alogliptin and pioglitazonePhase 3
Type 2 Diabetes Mellitus
Lapaquistat acetate and atorvastatinPhase 3
Hypercholesterolemia
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
